Part 5/6:
Despite the broader shift implied by his investment in the IBB, Campbell points out Soros’ isolated buy of Novavax, a company focused on developing a vaccine for a common respiratory virus affecting infants and the elderly. The timing of this purchase is intriguing, particularly as Novavax has recently achieved fast-track status for its vaccine, with potential Phase III data expected by the end of the year. The drug could feasibly reach the market within the next year if the trial results are favorable, marking an opportunity that hasn’t gone unnoticed by Soros.